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Objective: To compare the levels of plasma homocysteine (Hcy), vitamin B6 (vit-B6), serum 
vitamin B12 (vit-B12), and folate in healthy individuals and in patients with normal tension glau-
coma (NTG), pseudoexfoliative glaucoma (PXG), or primary open-angle glaucoma (POAG).
Study design: A prospective controlled trial.
Participants and methods: Forty healthy subjects, 48 patients with NTG, 38 patients 
with PXG, and 34 patients with POAG were included in the study. Those who used vitamin 
supplements or medications affecting Hcy and vitamin levels were excluded from the study. 
The levels of Hcy and vit-B6 were measured by High Performance Liquid Chromatography 
(HPLC). The levels of serum vit-B12 and folic acid were measured by competitive chemilu-
minescent enzyme immunoassay (CEI). One-way analysis if variance (ANOVA), analysis 
of covariance (ANCOVA), and the Tukey honestly significant difference test were used for 
statistical analysis.
Results: The mean Hcy level of the PXG group was 15.46 ± 9.27 µmol/L which was signifi-
cantly higher (P = 0.03) than that of the control group. There were no statistical differences 
in serum vit-B12 and folate levels among control subjects and NTG, PXG and POAG groups 
(P  0.05). It was found that the mean plasma vit-B6 level was significantly higher in subjects 
with NTG (P = 0.03) and POAG (P = 0.025) versus controls. Mean vit-B6 levels in NTG and 
POAG were 30.50 ± 11.29 µg/L and 30 ± 12.15 µg/L, respectively.
Conclusions: The plasma level of Hcy was found to be increased only in PXG patients and 
the plasma levels of vit-B6 were found to increase in the NTG and POAG sample groups. 
Using homocysteine and vit-B6 levels as the determinants of hyperhomocysteinemia still needs 
further research.
Keywords: normal tension glaucoma, pseudoexfoliative glaucoma, primary open-angle 
glaucoma, homocysteine, vitamin B6
Introduction
Glaucoma, which is characterized by retinal ganglion cell (RGC) apoptosis, is the 
prominent cause of blindness. RGC apoptosis may be the result of either impaired optic 
nerve head blood supply or direct toxic action due to various cytotoxic agents.1,2
Homocysteine (Hcy), an amino acid, is of interest as it has cytotoxic and vascu-
lopathic actions such as apoptosis of RGC, extracellular matrix alterations, oxidative 
stress, and ischemic vascular dysregulation.3–6 Recent focus on Hcy and glaucoma has 
yielded mixed results with some studies demonstrating an association with normal 
tension glaucoma (NTG), pseudoexfoliative glaucoma (PXG), and primary open-angle 
glaucoma (POAG), whilst others have not.7–15 Hcy metabolism is complex with both 
genetic and environmental factors. Differences in these factors could, in part, account Clinical Interventions in Aging 2010:5 134
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for the disparity in reported results. Vitamin B12, vitamin 
B6, and folate act as cofactors in Hcy metabolism. These 
vitamins are the major environmental determinants of Hcy 
level. Low folate, vitamin-B12 status, or renal impairment 
account for the majority of cases where increased Hcy is 
observed.16–19
As vitamin-B6, vitamin-B12, and folate are among the 
most common environmental factors to influence Hcy, we 
aimed to determine whether they exert this influence on 
homocysteine levels in open-angle glaucoma patients.
Participants and methods
Forty-eight patients with NTG, 38 patients with PXG, 
34 patients with POAG, and 40 healthy volunteers as controls 
were enrolled in this prospective controlled study. The study 
was designed according to the Helsinki Declaration and 
approved by the institutional ethic committee. Informed con-
sents were obtained from the patients and the volunteers.
All patients and the control subjects underwent a com-
plete ophthalmologic examination including best-corrected 
visual acuity, slit-lamp biomicroscopy, intraocular pressure 
(IOP) measurement using Goldmann applanation tonometry, 
gonioscopy, dilated fundoscopy using a 90-diopter lens, and 
visual field examination with full-threshold strategy program 
G-1, by an Octopus perimeter. The systemic examination 
was performed and a detailed medical story was obtained 
to identify the patients with risk factors for vascular disease 
such as hypertension, diabetes mellitus, hyperlipidemia, 
cardiovascular, and cerebrovascular diseases. Blood samples 
were collected at 0800 hours after overnight fasting in all 
subjects.
Inclusion criteria
Group 1
Control subjects had no history of ocular disease (except 
refractive error) and had a normal eye examination including 
normal IOP (22 mmHg), an open-angle, normal appearance 
of the optic disks and retinal nerve fiber layer, and normal 
visual fields.
Group 2
NTG patients were defined by the presence of glaucomatous 
cupping and visual field defect in at least one eye in two 
consecutive visits and an IOP lower than 22 mmHg.
Group 3
PXG was defined by the presence of typical pseudoexfolia-
tive material on the anterior lens capsule, an open-angle, 
IOP higher than 22 mmHg, typical glaucomatous cupping, 
and visual field defects in at least one eye in two consecutive 
visits.
Group 4
POAG was defined by the presence of an open-angle, IOP 
higher than 22 mmHg, typical glaucomatous cupping, and 
visual field defects in at least one eye in two consecutive 
visits.
Patients with cardiomyopathy or prior myocardial 
infarction, diabetes mellitus, systemic hypertension, 
peripheral or coronary artery disease, cerebrovascular 
disease, ocular inflammation, retinal occlusive disease, 
vasculitis, renal or hepatic dysfunction, gastrointestinal 
malabsorption, pregnancy, psychiatric illness, and/or 
chronic alcohol abuse were excluded from the study. 
Likewise, patients who used anticonvulsants and immu-
nosuppressives, hormone substitutes, cholesterol-lowering 
agents, antidepressants, recent antimicrobial therapy and 
vitamin supplements, plantary products, fish oil, or medi-
cations known to be associated with increased levels of 
Hcy, vitamins B6, B12, and folate, or patients with recent 
exposure (in the last three months) to anesthesia of nitrous 
oxide were also excluded.
Homocysteine, vitamin B6, vitamin B12,  
and folic acid assessment
Blood samples for vitamin-B12, vitamin-B6, folate, and Hcy 
were collected into a heparinized tube and transferred in 
ice blocks. The samples were then centrifuged at 4000 rpm 
for five minutes and stored at −20°C until the biochemical 
assay. Total Hcy (Recipe Chemicals, Munich, Germany) 
and vitamin-B6 levels were measured by HPLC (Shimadzu 
Corporation, Kyoto, Japan). The normal range for plasma 
Hcy and vitamin-B6 were 5–15 mol/L and 8.6–27.2 µg/L, 
respectively, in fasting subjects according to the manufac-
turers’ instruction.
The levels of serum vitamin-B12 and folate were mea-
sured by competitive CEI (Immulite 2000;-BIODPC, Los 
Angeles, CA. The normal serum values of vit-B12 and folate 
were 174–878 pg/mL and 3.1–17.5 ng/mL, respectively, 
according to manufacturer’s instruction.
Statistical analysis
Analysis of variance (one-way ANOVA) was performed to 
evaluate the differences in continuous variables (Hcy, vita-
min-B6, vitamin-B12, and folate) among the groups. The 
Tukey honestly significant difference (HSD) test was also Clinical Interventions in Aging 2010:5 135
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performed to evaluate the differences among the groups. 
Analysis of covariance (ANCOVA) was also used to adjust 
variables for vitamin-B12, vitamin-B6, and folate. A P value 
less than 0.05 was considered to be statistically significant. 
Statistical analyses were performed using SPSS software 
(version 10.0; SPSS Inc, Chicago, IL).
Results
The parametric one-way ANOVA test showed that the mean 
Hcy (0.006) and vitamin B6 (0.004) levels were significantly 
different among the groups.
The levels of Hcy and vitamins in the study groups are 
given in Table 1. The study groups were matched in terms 
of age and gender and there was no significant difference 
between the groups (P  0.05) (Table 2).
The mean Hcy level in the PXG group was 15.46 ± 
9.27 µmol/L and was significantly higher than that of the 
control (P = 0.003). The mean Hcy level in the control, NTG, 
and POAG groups were 8.68 ± 2.59, 11.27 ± 4.91, 11.28 ± 
4.80 µmol/L, respectively, and the mean Hcy level of the 
control group was not significantly different from those of the 
NTG and POAG groups (P  0.05) (Table 1, Figure 1).
The data pertaining to the vit-B12 levels in the groups 
are presented in Table 1 and Figure 2. The mean serum 
levels of vitamin-B12 were not different among the groups 
(P  0.05). Although it was not statistically significant, the 
PXG group had the lowest mean vitamin-B12 level among 
the study groups.
The data about folate in the groups are presented in 
Table 1 and Figure 3. There was no statistically significant 
difference among the groups (P  0.05). Similarly, the data 
about vitamin B6 in the groups are presented in Table 1 and 
Figure 4 and it was found that the mean vitamin B6 levels 
of the NTG (P = 0.01) and POAG (P = 0.025) groups were 
significantly higher versus the control one.
Additionally, in our study, analysis of covariance 
(ANCOVA) was also used to adjust variables for vitamin 
B12, vitamin B6, and folate because the levels of vitamin 
B12 and vitamin B6 were shown to be relatively different in 
group 3 (PXG sample) compared with the other glaucoma 
groups. The levels of Hcy were adjusted for these vitamins. 
Differences were not detected after adjusting for vitamin B12 
and vitamin B6 using ANCOVA.
Discussion
Elevated Hcy level is defined as an independent risk factor 
for atherosclerotic vascular disease and its plasma level is 
influenced by environmental and genetic factors. A high level 
of plasma Hcy is observed in disorders of Hcy metabolism, 
vitamin deficiencies, systemic arterial hypertension, diabetes 
mellitus, chronic renal insufficiency, and/or malign neo-
plasms. Additionally, habitual smoking and coffee intake, 
some medications, alcohol consumption, and physical activ-
ity may also affect Hcy levels.19,20
A number of studies have investigated the association of 
Hcy with different types of glaucoma including NTG, PXG, 
Table 1 Homocysteine, vitamin B6, vitamin B12, and folate levels in the study groups
Group Number  
of subjects
Hcy (µmol/L) Vitamin-B12 (pg/mL) Vitamin-B6 (µg/L) Folate (ng/mL)
Control 40 8.68 ± 2.59 345.55 ± 201.75 20.09 ± 5.54 9.00 ± 6.39
NTG 48 11.27 ± 4.91 344.46 ± 247.84 30.50 ± 11.29a 9.71 ± 3.86
PXG 38 15.46 ± 9.27a 277.16 ± 139.08 22.81 ± 11.71 10.82 ± 4.92
POAG 34 11.28 ± 4.80 368.24 ± 262.65 30.22 ± 12.15a 11.59 ± 9.40
Note: aIndicates statistically significant (P  0.05). 
Abbreviations: NTG, normal tension glaucoma; PXG, pseudoexfoliative glaucoma; POAG, primary open-angle glaucoma; Hcy, homocysteine.
Table 2 Gender and age data for study groups
Group Mean age and range Gender
Control 62 ± 8.1 years (range: 50–71) 18 males (45%) and 22 females (55%)
NTG 56 ± 6.8 years (range: 45–69) 24 males (50%) and 24 females (50%)
PXG 63 ± 6.3 years (range: 55–76) 20 males (52.63%) and 18 females (47.37%)
POAG 58 ± 7.5 years (range: 45–75) 14 males (41.18%) and 20 females (58.82%)
Abbreviations: NTG, normal tension glaucoma; PXG, pseudoexfoliative glaucoma; POAG, primary open-angle glaucoma.Clinical Interventions in Aging 2010:5 136
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and POAG. However, the results of these studies are still 
controversial. In the present study, Hcy levels were found 
to be significantly higher only in the PXG group and similar 
results have been reported in previous studies.10,11,21–27
Previous data suggest that an elevation in one’s Hcy level 
may cause changes in the optic nerve head microvasculature 
and impair optic nerve blood flow via a vasoconstrictive 
effect, endothelial injury, smooth muscle proliferation, 
platelet activation, thrombogenesis, and apoptotic cell death 
in retinal ganglion cells.28–33 This data might explain the 
relationship between the elevated levels of Hcy and neuronal 
cell death.
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Figure 1 Scatterplot demonstrating distribution of plasma homocysteine levels in 
the study groups.
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Figure 3 Scatterplot demonstrating distribution of serum folate levels in the study 
groups.
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Figure 2 Scatterplot demonstrating distribution of serum vitamin B12 levels in the 
study groups.
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Figure 4 Scatterplot demonstrating distribution of plasma vitamin B6 levels in the 
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Although it is not significant, vitamin B12 levels of 
the PXG sample were lowest among the groups in this 
study. Cumurcu et al and Puustjarvi et al have reported 
that the levels of serum vitamin B12 do not statistically 
differ between PXG and the other types of open-angle 
glaucoma.22,34 Conversely, Roedl et al have reported that 
the levels of serum vitamin B12 were significantly lower 
in the PXG group.35
In the case of Hcy metabolism, depression of vit-B12 is 
expected in the PXG group. According to previous data, it 
is well known that vitamin B12 deficiency may be one of the 
causes of hyperhomocysteinemia. This might be related to 
the fact that excess Hcy is converted to methionin by vitamin 
B12 in the organism and when vitamin B12 is deficient this 
above-mentioned conversion does not take place, resulting 
higher levels of Hcy. Similarly vitamin B12 levels of the 
POAG and the NTG groups are in the normal range. This 
might be related to the normal Hcy levels of these groups 
via the same metabolic process.35,36
The folate levels are in the normal range among all the 
groups in the present study. This is in accordance with the 
fact that Hcy metabolism is reversible via the pathway using 
folate21,35 and, therefore, the level of folate might not interfere 
with the level of Hcy.
In terms of Hcy metabolism, depression but not eleva-
tion of vitamin B6 is expected in the various glaucoma 
types. Whilst Puustjarvi et al reported that the level of 
serum vitamin B6 does not differ statistically between the 
PXG and control groups,34 Roedl et al found that levels of 
vitamin B6 were significantly lower in their PXG patients.35 
Vitamin B6, which is a cofactor in the catabolism of Hcy, 
increased in the POAG and NTG groups, whilst it is in the 
normal range in the PXG group. It might be speculated that 
the rate of the catabolism of vitamin B6 is probably high 
in the PXG patients resulting in a low catabolism rate of 
Hcy, causing higher Hcy levels. However, the molecular 
data about the catabolic utilization of vitamin B6 is lacking 
in this study. It is probable that actual vitamin B6 levels in 
PXG patients would be higher if vitamin B6 had not been 
used in Hcy catabolism.37 (Figure 5A).
High levels of plasma vitamin B6 in patients with POAG 
and NTG might be related, in part, with the deficiency or 
absence of enzymes such as 5-hydroxytryptophan decar-
boxylase and/or aromatic L-amino acid decarboxylase 
whose cofactor is vitamin B6, in the serotonin pathway37 
(Figure 5B). Meanwhile, a possible negative feed-back 
mechanism related to high serotonin levels might play a 
partial role in the decrease of the consumption of vitamin 
B6. Serotonin is a possible mediator of vasospasm and it 
influences blood viscosity, platelet aggregation, and vaso-
constriction. These actions are similar to those of Hcy. 
In addition to the above-mentioned actions, serotonin might 
lead to transient vasospasm of optic nerve head vessels 
and it may play a role in glaucomatous optic neuropathy 
in some eyes, particularly in NTG patients.38,39 However, 
serotonin, cysteine 5-hydroxytryptophan decarboxylase, 
and/or aromatic l-amino acid decarboxylase have not been 
measured in our study.
In conclusion, hyperhomocysteinemia was associated 
with PXG, while the vitamin B6 levels were increased in the 
Figure 5 A) Homocysteine catabolism to pyruvate and vitamin B6 (pyridoxine)-transaminase. B) Pathway for the synthesis of serotonin from tryptophan and pyridoxine as 
a coenzyme.
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NTG and POAG sample groups. We suggest that the levels of 
Hcy and B vitamins should be measured routinely in patients 
with glaucoma. This would aid to screen patients for life-
  threatening disorders related with hyperhomocysteinemia. 
We grant, the high levels of Hcy observed in the PXG group 
and the high levels of vitamin B6 detected in the NTG and 
POAG groups might be related with some compensatory 
  mechanisms or biochemical events that we could not under-
stand in either Hcy metabolism or genetic factors.
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